Share this article
Vaccine Blockchain Plan Prompts Enquiries Amid China Pharma Scandal
Following China's pharma scandal, investors are buying a firm's claim to be developing a vaccine-tracking blockchain, but one regulator isn't happy.
By Wolfie Zhao
Updated Sep 13, 2021, 8:13 a.m. Published Jul 26, 2018, 1:30 p.m.
On the back of China's most recent pharmaceutical scandal, stock investors are buying into a public company's claim to be developing a blockchain for tracking vaccines – but one watchdog isn't happy about it.
As reported by CoinDesk earlier this week, following a vaccine data scandal exposed last weekend, the Chinese crypto community weighed in with the argument that blockchain could be a potential solution for monitoring the vaccine supply chain.
STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
After the scandal broke, YLZ Info, a software company listed on China's Shenzhen Stock Exchange, announced that it is now planning to work with Alibaba payment affiliate Ant Financial to create a blockchain for just that purpose.
The claim followed a previous announcement made by the company in March indicating it was cooperating with Ant Financial on technological development in areas that include blockchain.
Perhaps unsurprisingly, YLZ's claim on Monday to be planning a specific vaccine blockchain project appears to have prompted keen interest from stock investors in the country.
Since the announcement, the company's stock price has surged by 10 percent on each of the past three days, recording a significant total spike of as much as a 50 percent and reaching an upper limit imposed by market regulators in China.
Given the stock surge, the Shenzhen Stock Exchange – which has the remit to regulate public firms to comply with securities law in China – sent an enquiry to the company on Wednesday night, demanding that YLZ deliver substantial proof of its capacity and resources in R&D of blockchain technology by Friday.
The exchange further demanded details regarding the firm's collaboration with Ant Financial on the topic – effectively asking whether the company is actually partnering to work on the vaccine project or merely harnessing blockchain hype in conjunction with a public crisis to juice up its stock price.
Vaccine image via Shutterstock
More For You
L1 tokens broadly underperformed in 2025 despite a backdrop of regulatory and institutional wins. Explore the key trends defining ten major blockchains below.
What to know:
2025 was defined by a stark divergence: structural progress collided with stagnant price action. Institutional milestones were reached and TVL increased across most major ecosystems, yet the majority of large-cap Layer-1 tokens finished the year with negative or flat returns.
This report analyzes the structural decoupling between network usage and token performance. We examine 10 major blockchain ecosystems, exploring protocol versus application revenues, key ecosystem narratives, mechanics driving institutional adoption, and the trends to watch as we head into 2026.
More For You
Crypto prices again muted as gold surges to new record, U.S. stocks advance
Bitcoin for the moment was unable to hold the $90,000 level reached prior to the U.S. market open.
What to know:
- Crypto prices are slipping a little during the U.S. trading session as precious metals and stocks move higher.
- The AI trade remains strong, with bitcoin miners who have pivoted business models moving sharply higher.
- Both gold and silver hit new records Monday and one analyst said bitcoin can't rally until those metals cool.
Top Stories
